片頭痛の治療におけるElismetrep(K-304)のランダム化された二重盲検、プラセボ対照研究
片頭痛の治療におけるElismetrep(K-304)の第IIB、無作為化、二重盲検、プラセボ対照研究:範囲の用量が評価されます
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35205
- Central Research Associates, LLC (CRA) dba Flourish Research
-
Mobile、Alabama、アメリカ、36608
- AMR Mobile
-
-
Arizona
-
Tucson、Arizona、アメリカ、85710
- Wake Research/ Tucson Neuroscience Research
-
-
California
-
Canoga Park、California、アメリカ、91303
- Hope Clinical Research
-
Encino、California、アメリカ、91316
- WR-PRI, LLC (Encino)
-
Huntington Beach、California、アメリカ、92647
- Marvel Clinical Research
-
La Mesa、California、アメリカ、91942
- Eximia Research - CA
-
Lemon Grove、California、アメリカ、91945
- Synergy San Diego
-
Newport Beach、California、アメリカ、92660
- WR-PRI, LLC (Newport Beach)
-
Oceanside、California、アメリカ、92056
- Excell Research, Inc.
-
Pomona、California、アメリカ、91767
- Empire Clinical Research
-
Riverside、California、アメリカ、92503
- Artemis Institute for Clinical Research - Riverside
-
San Diego、California、アメリカ、89109
- Acclaim Clinical Research
-
San Diego、California、アメリカ、92103
- Artemis Institute for Clinical Research - San Diego
-
Walnut Creek、California、アメリカ、94598
- Diablo Clinical Research, Inc.
-
West Hills、California、アメリカ、91307
- Focus Clinical Research
-
-
Connecticut
-
Cromwell、Connecticut、アメリカ、06416
- CT Clinical Research
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- DelRicht Research
-
Stockbridge、Georgia、アメリカ、30281
- Clinical Research Atlanta - Stockbridge
-
-
Idaho
-
Boise、Idaho、アメリカ、83704
- Northwest Clinical Trials
-
-
Illinois
-
Chicago、Illinois、アメリカ、60607
- Cedar Crosse Research Center
-
Flossmoor、Illinois、アメリカ、60422
- Healthcare Research Network II, LLC
-
-
Kansas
-
Overland Park、Kansas、アメリカ、66202
- Collective Medical Research
-
Wichita、Kansas、アメリカ、67207
- Alliance for Multispecialty Research
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40213
- L-MARC Research Center
-
-
Louisiana
-
Chalmette、Louisiana、アメリカ、70043
- Crescent City Headache & Neurology Center
-
New Orleans、Louisiana、アメリカ、70115
- DelRicht Research
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48104
- Michigan Head Pain and Neurological Institute
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55402
- Clinical Research Institute
-
-
Mississippi
-
Gulfport、Mississippi、アメリカ、39503
- DelRicht Research
-
-
Missouri
-
Hazelwood、Missouri、アメリカ、63042
- Healthcare Research Network
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89109
- Excel Clinical Research
-
North Las Vegas、Nevada、アメリカ、89119
- Las Vegas Clinical Trials
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87102
- Albuquerque Clinical Trials, Inc.
-
-
New York
-
Amherst、New York、アメリカ、14226
- Dent Neurosciences Research Center
-
Manlius、New York、アメリカ、13104
- CNY Clinical Research
-
Rochester、New York、アメリカ、14609
- Rochester Clinical Research
-
Williamsville、New York、アメリカ、14221
- Upstate Clinical Research Associates LLC
-
-
North Carolina
-
Greensboro、North Carolina、アメリカ、27405
- Headache Wellness Center
-
High Point、North Carolina、アメリカ、27260
- Peters Medical Research
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45212
- CTI Clinical Research Center
-
-
Oklahoma
-
Edmond、Oklahoma、アメリカ、73034
- OK Clinical Research, LLC
-
Oklahoma City、Oklahoma、アメリカ、73102
- Hightower Clinical
-
Tulsa、Oklahoma、アメリカ、74133
- DelRicht Research
-
Yukon、Oklahoma、アメリカ、73099
- Tekton Research
-
-
Oregon
-
Portland、Oregon、アメリカ、97210
- Summit Research Network
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Center for Clinical Research
-
Philadelphia、Pennsylvania、アメリカ、19114
- Clinical Research Philadelphia, LLC
-
Scottdale、Pennsylvania、アメリカ、15683
- Frontier Clinical Research, LLC
-
Smithfield、Pennsylvania、アメリカ、15478
- Frontier Clinical Research, LLC
-
West Chester、Pennsylvania、アメリカ、19380
- Atlas-Clinical
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29406
- Clinical Trials of South Carolina
-
North Charleston、South Carolina、アメリカ、29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37421
- WR-ClinSearch
-
Knoxville、Tennessee、アメリカ、37909
- AMR Knoxville (Formerly NOCCR)
-
Nashville、Tennessee、アメリカ、37203
- Clinical Research Associates, Inc.
-
-
Texas
-
Austin、Texas、アメリカ、78745
- Tekton Research
-
Austin、Texas、アメリカ、78737
- Donald J Garcia Jr, MD, PA
-
Dallas、Texas、アメリカ、75251
- FutureSearch Trials of Dallas, LP
-
Houston、Texas、アメリカ、77024
- Victorium Clinical Research LTD CO
-
Splendora、Texas、アメリカ、77372
- APD Clinical Research
-
Waxahachie、Texas、アメリカ、75165
- ClinPoint Trials
-
-
Utah
-
Ogden、Utah、アメリカ、84405
- Advanced Research Institute
-
-
Virginia
-
Newport News、Virginia、アメリカ、23606
- Health Research of Hampton Roads, Inc.
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26505
- Frontier Clinical Research, LLC
-
-
Wisconsin
-
Kenosha、Wisconsin、アメリカ、53144
- Clinical Investigation Specialist
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.
-
Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.
-
Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).
-
Meet the following requirements:
-
Is a male OR
-
Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:
-
Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.
-
Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.
OR
-
Is a female of reproductive potential and:
-
agrees to remain abstinent from heterosexual activity*
*Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
-
or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:
-
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- oral
- intravaginal
- transdermal
-
progestogen-only hormonal contraception associated with inhibition of ovulation:
- oral
- injectable
- implantable
-
intrauterine device (IUD)
-
intrauterine hormone-releasing system (IUS)
-
bilateral tubal occlusion
-
vasectomised partner
-
sexual abstinence
-
progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
-
male or female condom with or without spermicide
-
cap, diaphragm or sponge with spermicide
-
A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)
-
This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).
-
-
Participant voluntarily agrees to participate in the study by giving written informed consent.
-
Participant is able to read, understand and complete the study questionnaires and diary.
-
Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.
-
Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.
Exclusion Criteria:
-
Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.
Migraine history related
-
Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.
-
Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.
-
Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).
-
Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.
-
Participant was >50 years old at age of first migraine onset.
-
Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.
Medical history related
-
Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].
-
Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.
-
Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
-
Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.
-
Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.
-
Has a history of human immunodeficiency virus disease.
-
Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.
Laboratory, vital sign, and electrocardiogram (ECG) related
-
Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.
-
Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.
-
Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.
-
Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.
-
Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.
Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.
Medication use and substance abuse related
-
Has known history of or suspected abuse of alcohol or recreational drugs at screening.
-
Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.
-
Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.
-
Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.
-
Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.
-
History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.
-
History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.
Other
-
Has known or suspected hypersensitivity to trial product(s) or related products.
-
Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
-
Has any surgery scheduled for the duration of the trial.
-
Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).
-
Has previous participation in this trial. Participation is defined as signed informed consent.
-
Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.
-
Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
-
Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Elismetrep (K-304) Dose Level 1
Participants received a single dose of elismetrep 2 mg |
Administered orally |
|
実験的:Elismetrep (K-304) Dose Level 2
Participants received a single dose of elismetrep 5 mg |
Administered orally |
|
実験的:Elismetrep (K-304) Dose Level 3
Participants received a single dose of elismetrep 10 mg |
Administered orally |
|
実験的:Elismetrep (K-304) Dose Level 4
Participants received a single dose of elismetrep 20 mg |
Administered orally |
|
プラセボコンパレーター:Placebo
Participants received a single dose of elismetrep-matched placebo |
Administered orally |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain Freedom
時間枠:2 hours post-dose
|
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) |
2 hours post-dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
時間枠:up to 7 days after administration of study therapy
|
up to 7 days after administration of study therapy
|
|
|
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
時間枠:2 hours post-dose
|
Assessed using the number of evaluable participants that reported the absence of their MBS |
2 hours post-dose
|
|
Pain Relief
時間枠:2 hours post-dose
|
Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1). |
2 hours post-dose
|
|
Freedom From Photophobia
時間枠:2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline. |
2 hours post-dose
|
|
Freedom From Phonophobia
時間枠:2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline. |
2 hours post-dose
|
|
Freedom From Nausea
時間枠:2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline. |
2 hours post-dose
|
|
The Probability of Requiring Rescue Medication
時間枠:24 hours post-dose
|
Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy |
24 hours post-dose
|
|
Sustained Pain Freedom
時間枠:From 2 to 24 hours
|
Assessed using the number of participants that did not experience any headache pain through the time period of interest |
From 2 to 24 hours
|
|
Sustained Pain Relief
時間枠:From 2 to 24 hours
|
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
From 2 to 24 hours
|
|
Sustained Pain Freedom
時間枠:From 2 to 48 hours
|
Assessed using the number of participants that did not experience any headache pain through the time period of interest. |
From 2 to 48 hours
|
|
Sustained Pain Relief
時間枠:From 2 to 48 hours
|
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
From 2 to 48 hours
|
|
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
時間枠:Up to 7 days after administration of study therapy
|
Serious adverse events were assessed in the Safety Analysis Set. |
Up to 7 days after administration of study therapy
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。